TY  - GEN
AU  - Yang,Hong
AU  - Higgins,Brian
AU  - Kolinsky,Kenneth
AU  - Packman,Kathryn
AU  - Bradley,William D
AU  - Lee,Richard J
AU  - Schostack,Kathleen
AU  - Simcox,Mary Ellen
AU  - Kopetz,Scott
AU  - Heimbrook,David
AU  - Lestini,Brian
AU  - Bollag,Gideon
AU  - Su,Fei
TI  - Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
SN  - 1538-7445
PY  - 2012///0330
KW  - Animals
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Area Under Curve
KW  - Bevacizumab
KW  - Blotting, Western
KW  - Camptothecin
KW  - Capecitabine
KW  - Cell Line, Tumor
KW  - Cell Proliferation
KW  - drug effects
KW  - Cetuximab
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Deoxycytidine
KW  - Dose-Response Relationship, Drug
KW  - Drug Resistance, Neoplasm
KW  - Erlotinib Hydrochloride
KW  - Fluorouracil
KW  - HCT116 Cells
KW  - HT29 Cells
KW  - Humans
KW  - Indoles
KW  - Irinotecan
KW  - Kaplan-Meier Estimate
KW  - Mice
KW  - Mice, Nude
KW  - Mitogen-Activated Protein Kinases
KW  - metabolism
KW  - Mutation
KW  - Phosphorylation
KW  - Proto-Oncogene Proteins B-raf
KW  - antagonists & inhibitors
KW  - Quinazolines
KW  - Sulfonamides
KW  - Vemurafenib
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/0008-5472.CAN-11-2941
ER  -